Do you have the same question? Follow this Question
Oct 23, 2025 - 11:07 AM
We’ve provided several answers to questions related to Entyvio (Vedolizumab) , see some other helpful Q&A related to this product.
Question: What conditions is this medication used to treat?
Answer: It is used to treat adults with moderate-to-severe ulcerative colitis or Crohn’s disease. This indication provides valuable relief for individuals living with these chronic inflammatory bowel diseases.
Question: What is the ChEBI code for vedolizumab?
Answer: The ChEBI code is CHEBI:134721. ChEBI codes are used for chemical entity identification in biomedical research.
Question: What licenses or approvals does this medication have?
Answer: The medication is licensed by the US FDA (United States Food and Drug Administration) and EMA (European Medicines Agency). FDA and EMA approval provides assurance of the medication’s safety and effectiveness as reviewed by major regulatory bodies.
Question: What are the routes of administration for this medication?
Answer: The medication can be administered either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection. These options provide flexibility for patients and healthcare providers, allowing for administration based on patient preference or clinical needs.
